Published in J Immunol on January 01, 2008
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol (2012) 1.13
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy (2010) 1.04
Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS One (2011) 1.03
Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol (2014) 1.02
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood (2013) 0.99
Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol (2008) 0.95
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood (2008) 0.95
Host-based Th2 cell therapy for prolongation of cardiac allograft viability. PLoS One (2011) 0.85
Harnessing autophagy for adoptive T-cell therapy. Immunotherapy (2012) 0.81
Harnessing autophagy for cell fate control gene therapy. Autophagy (2013) 0.81
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clin Cancer Res (2011) 0.79
The use of donor-derived veto cells in hematopoietic stem cell transplantation. Front Immunol (2012) 0.78
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res (2015) 0.78
Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells. Cytotherapy (2013) 0.78
Rapamycin resistant murine th9 cells have a stable in vivo phenotype and inhibit graft-versus-host reactivity. PLoS One (2013) 0.75
BATF inhibition prevent acute allograft rejection after cardiac transplantation. Am J Transl Res (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res (2012) 3.35
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A (2011) 2.58
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med (2011) 2.04
Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell (2011) 1.94
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 1.84
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res (2004) 1.73
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol (2004) 1.62
Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol (2011) 1.61
STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity (2012) 1.56
Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med (2008) 1.53
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood (2004) 1.48
CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48
Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones (2002) 1.37
Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell (2012) 1.35
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol (2010) 1.35
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood (2008) 1.28
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 1.27
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
Response selectivity for species-specific calls in the inferior colliculus of Mexican free-tailed bats is generated by inhibition. J Neurophysiol (2002) 1.23
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res (2004) 1.22
Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat Struct Mol Biol (2009) 1.22
Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood (2008) 1.20
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant (2013) 1.18
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res (2008) 1.17
Interleukin 7 worsens graft-versus-host disease. Blood (2002) 1.16
Media reporting of tenofovir trials in Cambodia and Cameroon. BMC Int Health Hum Rights (2005) 1.15
Are we making progress in GVHD prophylaxis and treatment? Hematology Am Soc Hematol Educ Program (2012) 1.14
Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol (2005) 1.12
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther (2004) 1.12
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem (2001) 1.10
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2006) 1.10
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res (2012) 1.09
Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther (2004) 1.09
Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell (2013) 1.08
Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. Clin Transl Sci (2009) 1.08
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol (2008) 1.07
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis (2003) 1.07
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol Blood Marrow Transplant (2006) 1.06
Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. Am J Pathol (2007) 1.05
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy (2010) 1.04
A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol (2007) 1.04
Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant (2008) 1.04
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res (2011) 1.04
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol (2002) 1.03
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther (2008) 1.03
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res (2007) 1.01
A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One (2009) 1.01
Chromosomal protein HMGN1 modulates the expression of N-cadherin. FEBS J (2005) 1.01
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res (2013) 1.00
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 0.99
Development and organization of polarity-specific segregation of primary vestibular afferent fibers in mice. Cell Tissue Res (2010) 0.98
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood (2003) 0.98
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant (2003) 0.98
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant (2005) 0.97
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J Biol Chem (2009) 0.97
Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. Am J Pathol (2010) 0.97
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs (2009) 0.96
Impaired rearrangement of IgH V to DJ segments in bone marrow Pro-B cells from old mice. Cell Immunol (2003) 0.96
Hydrogen sulfide is an endogenous potentiator of T cell activation. J Biol Chem (2011) 0.96
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Med Chem (2013) 0.96
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood (2008) 0.95
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer (2008) 0.94
mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein. J Biol Chem (2009) 0.92
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer (2011) 0.91
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Transplant (2010) 0.91
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood (2012) 0.90
Stressing the development of small molecules targeting HSP90. Clin Cancer Res (2013) 0.90
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle (2012) 0.90
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol (2004) 0.89